TY  - JOUR
T1  - GUideline supports long-term use of medication to lower prostate cancer risk
AU  - Mitka M
Y1  - 2009/05/06
N1  - 10.1001/jama.2009.560
JO  - JAMA
SP  - 1753
EP  - 1754
VL  - 301
IS  - 17
N2  - 
The guideline, issued February 24 by an expert panel jointly convened by the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA), focuses on men with a prostate-specific antigen (PSA) level of 3.0 ng/mL or less who are regularly screened with a PSA test or who are considering receiving an annual PSA test. Physicians are directed to tell these patients that they may benefit from taking a 5-α-reductase inhibitor (5 mg/d of finasteride) for 7 years to prevent prostate cancer (Kramer BS et al. J Urol. 2009;181[4]:1642-1657).

SN  - 0098-7484
M3  - doi: 10.1001/jama.2009.560
UR  - http://dx.doi.org/10.1001/jama.2009.560
ER  -